Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab

Clinical trial NCT04266730 · SUSPENDED

Trial details

NCT number: NCT04266730
Sponsor: UNC Lineberger Comprehensive Cancer Center
Status: SUSPENDED
Phase: Phase 1
Study type: INTERVENTIONAL

Squamous Cell Lung Cancer Squamous Non-small Cell Lung Cancer Squamous Cell Carcinoma of Head and Neck

Start date: 2027-05-20
Primary completion: 2027-06-01
Enrollment: 6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.